- Associated Press - Tuesday, August 18, 2015

PORTLAND, Ore. (AP) - Oregon will get $2.2 million from drugmaker Amgen following a multi-state investigation into the company’s marketing of two drugs.

Oregon and Illinois led the investigation on behalf of 48 states and the District of Columbia. The states allege Amgen marketed Aranesp, an anemia drug, and Enbrel, used to treat plaque psoriasis, for purposes not approved by the Food and Drug Administration.

Under a settlement announced Tuesday, Amgen will pay $71 million. Oregon’s share will go to an account that funds investigations into unlawful business practices.

Attorney General Ellen Rosenblum’s office says settlements with drug companies and medical device makers have brought Oregon nearly $15 million since last summer.

Amgen said it is pleased to have resolved the matters and that it has a strong legal compliance program.


Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide